Results 81 to 90 of about 4,821 (183)

G protein-coupled receptors: what a difference a 'partner' makes [PDF]

, 2014
G protein-coupled receptors (GPCRs) are important cell signaling mediators, involved in essential physiological processes. GPCRs respond to a wide variety of ligands from light to large macromolecules, including hormones and small peptides. Unfortunately,
Abu-Helo, Aiyar, Ardura, Attramadal, Babu, Baker, Bartlett, Behrens, Benovic, Benoît Roux, Bermak, Beuming, Björk, Bofill-Cardona, Bomberger, Bornert, Bouschet, Bradbury, Brady, Bretscher, Buck, Buhlmann, Bukau, Bécamel, Cabrera-Vera, Cai, Cao, Caron, Chabre, Chakraborty, Chan, Chen, Cheung, Christopoulos, Christopoulos, Chung, Claing, Clark, Clark, Clark, Colley, Cone, Cook, Cottrell, Cowen, Craig, Dackor, Dackor, Dores, Dunn, Dupré, Dupré, Dwyer, Décaillot, Egea, Ellgaard, Ellis, Evans, Evron, Fam, Ferguson, Ferreira, Fiedler, Fluhmann, Force, Fraser, Fredriksson, Gage, Gardner, Gerke, Gimelbrant, Girard, Goadsby, Graeme Cottrell, Gullapalli, Hamm, Han, Hay, Heydorn, Hilairet, Hilairet, Humrich, Jones, Kadmiel, Kadmiel, Kakiuchi, Kang, Kappeler, Kelley, Kennedy, Kjeldgaard, Kristiansen, Kuang, Kurten, Laburthe, Leclerc, Lee-Kwon, Levitt, Li, Lin, Lohse, Lu, Lucas, Luebke, Lukov, Lutz-Bucher, Ma, Mahon, Mahon, Mahon, Mai, Mancias, Marchese, Marenholz, McClintock, McClintock, McLatchie, Metherell, Miret, Montecucchi, Morello, Mountjoy, Muff, Murphy, Murrell, Málaga-Diéguez, Naghashpour, Nakajima, Nickols, Nikitenko, Nisar, Nishimura, Njuki, Noon, Noorwez, Oh, Oh, Okuse, Oliver, Overgaard, O’Neill, Paquet, Park, Parmentier, Petaja-Repo, Pfeffer, Pittman, Ponting, Prado, Premont, Pálfy, Ritter, Rivero-Müller, Rochdi, Roh, Romero, Rosenblatt, Saito, Sapolsky, Sarkar, Schmidt, Sebag, Sebag, Shenoy, Shieh, Simonin, Sorensen, Spehr, Stamnes, Strasser, Svenningsson, Svenningsson, Tan, Tsujikawa, Turner, Voeltz, Vos, Walther, Wang, Wang, Wang, Wang, Wang, Warner-Schmidt, Warner-Schmidt, Webb, Whistler, Wootten, Yamniuk, Yang, Zobiack   +190 more
core   +4 more sources

Adjunctive therapy for glucose control in patients with type 1 diabetes

Diabetes, Metabolic Syndrome and Obesity, 2018
Kira Harris,1,2 Cassie Boland,1,3 Lisa Meade,1,4 Dawn Battise1,5 1Pharmacy Practice Faculty, Wingate University School of Pharmacy, Wingate, NC, USA; 2Clinical Pharmacy Specialist – Novant Health Family Medicine Residency Program, Cornelius, NC ...
Harris K, Boland C, Meade L, Battise D
doaj  

Transitions of Care for People with Type 2 Diabetes: Utilization of Antihyperglycemic Agents Pre- and Post-Hospitalization [PDF]

, 2015
INTRODUCTION: Little research to date has examined antihyperglycemic agent (AHA) utilization among patients with type 2 diabetes mellitus (T2DM) around transitions of care from inpatient to outpatient settings. Discontinuity of care between inpatient and
Donna McMorrow, Leslie Montejano, Lien Vo   +2 more
core   +1 more source

Preoptic Inputs and Mechanisms that Regulate Maternal Responsiveness [PDF]

, 2014
The preoptic area is a well-established centre for the control of maternal behaviour. An intact medial preoptic area (mPOA) is required for maternal responsiveness because lesion of the area abolishes maternal behaviours. Although hormonal changes in the
Dobolyi, Árpád, Grattan, D. R., Stolzenberg, D. S.   +2 more
core   +1 more source

Control of energy homeostasis by amylin [PDF]

, 2018
Amylin is an important control of nutrient fluxes because it reduces energy intake, modulates nutrient utilization by inhibiting postprandial glucagon secretion, and increases energy disposal by preventing compensatory decreases of energy expenditure in ...
Lutz, Thomas
core  

Photoaffinity cross-linking and unnatural amino acid mutagenesis reveal insights into calcitonin gene-related peptide binding to the calcitonin receptor-like receptor/receptor activity-modifying protein 1 (CLR/RAMP1) complex [PDF]

, 2018
Calcitonin gene-related peptide (CGRP) binds to the complex of the calcitonin receptor-like receptor (CLR) with receptor activity-modifying protein 1 (RAMP1).
Brimble, Margaret A, Garelja, Michael L, Gingell, Joseph J, Harris, Paul WR, Hay, Debbie L, Poyner, David R, Reynolds, Christopher A, Sakmar, Thomas P, Simms, John, Uddin, Romez   +9 more
core   +3 more sources

Mitochondrial Adaptations in Skeletal Muscle Following Incretin‐Based Therapies: In Vitro

Journal of Cachexia, Sarcopenia and Muscle
Background Incretin‐based therapies such as glucagon‐like peptide‐1 receptor agonists (GLP‐1Ras), dual GLP‐1/GIP agonists and amylin analogues have demonstrated significant weight loss benefits.
Victoria Old, Melanie Davies, Matthew Denniff, Pratik Choudhary, Nicholas Eastley, Robert U. Ashford, Emma Watson   +6 more
doaj   +1 more source

The dual amylin and calcitonin receptor agonist KBP-336 elicits a unique combination of weight loss, antinociception and bone protection – a novel disease-modifying osteoarthritis drug

Arthritis Research & Therapy
Background Despite the extensive research to provide a disease-modifying osteoarthritis drug (DMOAD), there is still no approved DMOAD. Dual amylin and calcitonin receptor agonists (DACRA) can provide metabolic benefits along with antinociceptive and ...
Khaled Elhady Mohamed, Anna Thorsø Larsen, Simone Melander, Frederik Andersen, Ellen Barendorff Kerrn, Morten Asser Karsdal, Kim Henriksen   +6 more
doaj   +1 more source

Efficacy and Safety of Taspoglutide Versus Sitagliptin for Type 2 Diabetes Mellitus (T-Emerge 4 Trial) [PDF]

, 2012
INTRODUCTION: The efficacy and safety of taspoglutide, a long-acting human glucagon-like peptide-1 analog, were compared with sitagliptin or placebo, as adjunct to metformin, in patients with inadequately controlled type 2 diabetes.
Adriana Forti, Jean-Louis Chiasson, Mark Boldrin, Michael Woloschak, Raffaella Balena, Richard M. Bergenstal   +5 more
core   +1 more source

Comparative Efficacy and Safety of Semaglutide, Cagrilintide, and CagriSema in Adults with Overweight or Obesity: A Bayesian Network Meta-Analysis

Journal of Clinical Question
Introduction: Incretin-based therapies, including glucagon-like peptide-1 receptor agonists and amylin analogues, have emerged as promising treatments for obesity.
Yange Meng, Ting Jin, Luping Ren, Michelle L. Thompson, Yue Wang   +4 more
doaj   +1 more source